PPARG anticorps (N-Term)

N° du produit ABIN966886

Détail du produit anti-PPARG anticorps

Antigène: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Épitope: N-Term

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp PPARG est non-conjugé

Application: Western Blotting (WB)

Réactivité croisée (Details): No cross reactivity with other proteins.

Attributs du produit: Rabbit IgG polyclonal antibody for Peroxisome proliferator-activated receptor gamma ( PPARG) detection. Tested with WB in Human.

Immunogène: A synthetic peptide corresponding to a sequence at the N-terminal of human PPAR-G, different from the rat and mouse sequences by two amino acids.< br/>Immunogen was affinity purified.

Isotype: IgG

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 µg/mL.

Buffer: Each vial contains 5 mg BSA, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Thimerosal, 0.05 mg Sodium azide.

Agent conservateur: Sodium azide, Thimerosal (Merthiolate)

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: At -20 °C for one year. After reconstitution, at 4 °C for one month. It can also be aliquotted and stored frozen at -20 °C for a longer time.

Références pour anticorps anti-PPARG (ABIN966886)

Ameshima, Golpon, Cool, Chan, Vandivier, Gardai, Wick, Nemenoff, Geraci, Voelkel: "Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth." dans: Circulation research, Vol. 92, Issue 10, pp. 1162-9, (2003) (PubMed).

Berger, Moller: "The mechanisms of action of PPARs." dans: Annual review of medicine, Vol. 53, pp. 409-35, (2002) (PubMed).

Deeb, Fajas, Nemoto, Pihlajamäki, Mykkänen, Kuusisto, Laakso, Fujimoto, Auwerx: "A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity." dans: Nature genetics, Vol. 20, Issue 3, pp. 284-7, (1998) (PubMed).

Détails sur PPARG

Antigène: PPARG (Peroxisome Proliferator-Activated Receptor gamma (PPARG))

Abstract: PPARG Produits

Synonymes: anticorps PPAR gamma, anticorps PPARg2, anticorps PPARG, anticorps Nr1c3, anticorps PPAR-gamma, anticorps PPAR-gamma2, anticorps PPARgamma, anticorps PPARgamma2, anticorps NR1C3, anticorps CIMT1, anticorps GLM1, anticorps PPARG1, anticorps PPARG2, anticorps xPPAR-gamma, anticorps PPAR-GAMMA, anticorps PPARGAMMA, anticorps peroxisome proliferator-activated receptor gamma, anticorps peroxisome proliferator activated receptor gamma, anticorps peroxisome proliferator activated receptor gamma L homeolog, anticorps PPARG, anticorps Pparg, anticorps pparg.L

Sujet: The peroxisome proliferator-activated receptors (PPARs) are a group of three nuclear receptor isoforms, PPAR gamma, PPAR alpha, and PPAR delta, encoded by different genes. PPARs are ligand-regulated transcription factors that control gene expression by binding to specific response elements (PPREs) within promoters. PPAR gamma is a transcription factor that has a pivotal role in adipocyte differentiation and expression of adipocyte-specific genes. The PPAR gamma1 and gamma2 isoforms result from alternative splicing and have ligand-dependent and -independent activation domains. PPAR gamma is a member of a family of nuclear receptors/ligand-dependent transcription factors, which bind to hormone response elements on target gene promoters. Ameshima et al. (2003) found that PPAR gamma is abundantly expressed in normal lung tissues, especially in endothelial cells, but that its expression is reduced or absent in the angiogenic plexiform lesions of pulmonary hypertensive lungs and in the vascular lesions of a rat model of severe pulmonary hypertension. And they conclude that fluid shear stress decreases the expression of PPARgamma in endothelial cells and that loss of PPARgamma expression characterizes an abnormal, proliferating, apoptosis-resistant endothelial cell phenotype.

Pathways: Signalisation MAPK, Nuclear Receptor Transcription Pathway, Steroid Hormone Mediated Signaling Pathway, Negative Regulation of Hormone Secretion, Carbohydrate Homeostasis, Regulation of Lipid Metabolism by PPARalpha, Positive Regulation of Endopeptidase Activity, Brown Fat Cell Differentiation, Positive Regulation of fat Cell Differentiation